Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights.

ABSTRACT: The global increase in cancer incidence presents significant economic and societal challenges. While chimeric antigen receptor-modified T cell (CAR-T) therapy has demonstrated remarkable success in hematologic malignancies and has earned FDA approval, its translation to solid tumors encounters faces significant obstacles, primarily centered around identifying reliable tumor-associated antigens and navigating the complexities of the tumor microenvironment. Recent developments in single-cell RNA sequencing (scRNA-seq) have greatly enhanced our understanding of tumors by offering high-resolution, unbiased analysis of cellular heterogeneity and molecular patterns. These technologies have revolutionized our comprehension of tumor immunology and have led to notable progress in cancer immunothera

SUBMITTER: Pu Z 

PROVIDER: S-EPMC10712310 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature